Remove Events Remove Healthcare Remove Medical science
article thumbnail

Pharmaceutical Sales Representative VS. Medical Science Liaison

Pharmaceutical Representative Training

As the healthcare industry evolves with novel and innovative therapies, it brings the need for highly specialized conversations with healthcare providers (HCPs) and key opinion leaders (KOLs). While the sales force is still a crucial part of any pharmaceutical company, the demand for Medical Affairs teams continue to rise.

article thumbnail

Dapagliflozin approved for heart failure across LVEFs

European Pharmaceutical Review

The Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted a licence extension for FORXIGA (dapagliflozin) in Great Britain for symptomatic chronic heart failure (HF) across the full spectrum of left ventricular ejection fraction (LVEF).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

10 Ways AI/ML Technologies Can Enhance Software Quality in the Life Sciences Industry

PM360

Food & Drug Administration’s proposed Computer System Assurance (CSA) guidelines, the old methods of unit tests and standardized manual and automated testing are no longer adequate for ensuring both solution security and healthcare outcomes. The good news?

article thumbnail

How Asia Pacific Medical Teams are Using Real-Time Data to Transform Interactions with Experts

Veeva

One of the biggest challenges for MSLs is finding accurate, real-time information on KOLs in the healthcare industry. This is particularly important due to the high value of an interaction between medical science liaisons (MSLs) and (key opinion leaders) KOLs. The answer to these questions is yes.

Medical 52
article thumbnail

From Volume-to-Value—The Critical Role of EHR

PM360

The adoption of Electronic Health Records (EHRs) had been a slow process until 2009 when federal incentives to healthcare professionals (HCPs) to switch from paper to EHR charts became available, and when HCPs were rewarded via higher payments for meeting meaningful use criteria. Advance Medical Science.

article thumbnail

Biologic Prices Decreasing As More Commercial Health Plans Allow Biosimilars as First-Line Options

PM360

When the first biosimilars were approved by the FDA almost a decade ago, they were expected to provide a cost-effective alternative to expensive biologics, improve accessibility for patients and reduce healthcare spending by creating competition in the biologic market. Regional Account Manager, and Shaun Terry, Sr.

article thumbnail

The (inevitable) digital transformation of Medical Affairs

Impetus Digital

Healthcare providers (HCPs), payers, and patients can now access medical information at their fingertips and they expect more from Pharma than in the past. The pandemic accelerated the uptake of virtual meeting and event technologies. MA is empowered to shape new standards in communication of medical information.

Medical 52